Dementia Sees The Most Exponential Increase In Chronic Disease Burden

Awareness Of Vascular Disease-Dementia Link Heralds Treatment Progress

Josef Coresh, founding director of the Optimal Aging Institute at NYU Grossman School of Medicine, talks about his ongoing research to mark Alzheimer’s and Brain Awareness Month.

Alzheimer memory loss due to Dementia and brain disease with the abstract medical icon of a human head and neurology research as a 3D illustration.

The science of aging and aging well is in good health. In the US, the number of adults over 65 is set to exceed those under 18 for the first time by 2034. But in tandem, research on the risk factors of aging and optimal aging is going from strength to strength.

More from Innovation

HealthTech Innovation Versus Clinician And System Awareness

 
• By 

Bringing AI and digital healthtech innovation to patients works most efficiently via a three-way partnership in which clinicians and cloud services have equal weighting with a powerhouse innovator, Royal Philips told In Vivo during ECR 2025.

Podcast: Meet Grace, The Clinical Trial AI Agent

 
• By 

In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based AI agent to streamline clinical trial processes.

Barcelona Health Hub: Where Digital Health Innovation Meets Historic Art Nouveau

 
• By 

The Barcelona Health Hub is a nonprofit that seeks to advance digital health innovation by bringing together start-ups, investors, health care institutions and corporations.

Aurion Biotech’s Ophthalmic Cell Therapy For The Masses

 
• By 

Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.

More from In Vivo

TechBio’s Next Wave: Where AI Meets Biology And Investment Opportunity

 
• By 

TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.

Deals In Depth: February 2025

 
• By 

Three $1bn+ alliances were penned in February, and one exceeded $2bn.

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth

 
• By 

From a $7m discarded asset to a $336m commercial portfolio, In Vivo looks inside Mirum Pharma’s disciplined strategy for identifying, acquiring and revitalizing overlooked rare disease programs while building toward billion-dollar potential.